TherapeuticsMD, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

TXMD$1.69-2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except per share amounts)

	Years ended December 31,
	2025	2024
Revenue, net:
License revenue	$3,022	$1,761
Operating expenses:
General and administrative	6,852	6,096
Write-off and impairment of patents	176	1,268
Depreciation & amortization	384	509
Total operating expenses	7,412	7,873
Loss from operations	(4,390)	(6,112)
Other income (expense):
Interest income, net	142	135
Sublease income	1,847	1,352
Miscellaneous income	1,748	2,282
Total other income	3,737	3,769
Loss from continuing operations before income taxes	(653)	(2,343)
Income tax benefit	—	31
Net loss from continuing operations	(653)	(2,312)
Income from discontinued operations, net of income taxes	84	131
Net loss	$(569)	$(2,181)
(Loss) income per common share, basic:
Continuing operations	$(0.06)	$(0.20)
Discontinued operations, net	0.01	0.01
Net loss per common share, basic	$(0.05)	$(0.19)
(Loss) income per common share, diluted:
Continuing operations	$(0.06)	$(0.20)
Discontinued operations, net	0.01	0.01
Net loss per common share, diluted	$(0.05)	$(0.19)
Weighted average common shares, basic	11,569	11,532
Weighted average common shares, diluted	11,569	11,532

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.